ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.

Kalindi Parmar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.